| Literature DB >> 35269165 |
Nehal E Elsadek1, Abdalrazeq Nagah2, Tarek M Ibrahim3, Hitesh Chopra4, Ghada A Ghonaim2, Sherif E Emam3, Simona Cavalu5, Mohamed S Attia3.
Abstract
Electrospinning (ES) has become a straightforward and customizable drug delivery technique for fabricating drug-loaded nanofibers (NFs) using various biodegradable and non-biodegradable polymers. One of NF's pros is to provide a controlled drug release through managing the NF structure by changing the spinneret type and nature of the used polymer. Electrospun NFs are employed as implants in several applications including, cancer therapy, microbial infections, and regenerative medicine. These implants facilitate a unique local delivery of chemotherapy because of their high loading capability, wide surface area, and cost-effectiveness. Multi-drug combination, magnetic, thermal, and gene therapies are promising strategies for improving chemotherapeutic efficiency. In addition, implants are recognized as an effective antimicrobial drug delivery system overriding drawbacks of traditional antibiotic administration routes such as their bioavailability and dosage levels. Recently, a sophisticated strategy has emerged for wound healing by producing biomimetic nanofibrous materials with clinically relevant properties and desirable loading capability with regenerative agents. Electrospun NFs have proposed unique solutions, including pelvic organ prolapse treatment, viable alternatives to surgical operations, and dental tissue regeneration. Conventional ES setups include difficult-assembled mega-sized equipment producing bulky matrices with inadequate stability and storage. Lately, there has become an increasing need for portable ES devices using completely available off-shelf materials to yield highly-efficient NFs for dressing wounds and rapid hemostasis. This review covers recent updates on electrospun NFs in nanomedicine applications. ES of biopolymers and drugs is discussed regarding their current scope and future outlook.Entities:
Keywords: biopolymers; electrospinning; implants; nanofibers; nanomedicine; targeted delivery; wound healing
Year: 2022 PMID: 35269165 PMCID: PMC8911671 DOI: 10.3390/ma15051934
Source DB: PubMed Journal: Materials (Basel) ISSN: 1996-1944 Impact factor: 3.623
Figure 1Techniques for nanofiber production.
Figure 2Ex vivo imaging of collected organs (1 tumor, 2 hearts, 3 livers, 4 spleens, 5 lungs and 6 kidneys) at 1, 24 and 48 h following the implantation of electrospun nanofibers into the mice’s vaginas. Reprinted with permission from ref. [36].
Figure 3Coaxial electrospinning-prepared implantable Doxorubicin-loaded micelles in NFs for effective cancer therapy. Reprinted with permission from ref. [40].
Multidrug-loaded electrospun NF implants for cancer treatment.
| Polymeric Fiber | ES Technique | Drugs | Type of Cancer | In Vivo | In Vitro | Ref. |
|---|---|---|---|---|---|---|
| BIC/(PLGA) | Blend ES | CAR, CIS and CPT-11 | Brain cancer (C6 glioma) | + | [ | |
| Blend ES | 5-FU and oxaliplatin | Colorectal cancer (HCT8 and CT26 cell lines) | + | + | [ | |
| PGC-C18/PCL | Blend ES | CPT-11 and SN-38 | Human colorectal (HT-29) cell line | + | [ | |
| PLGA/gelatin | Blend ES | DOX-encapsulated mesoporous zinc oxide microspheres /camptothecin | Liver cancer (HepG2) cell line | + | [ | |
| PEG/PLA | Blend ES | CBT A-4 and HCPT | Breast (4T1) tumor model | + | + | [ |
| Emulsion ES | Paclitaxel and DOX | Brain cancer (C6 glioma) | + | [ | ||
| Dextran/PLGA | Emulsion ES | HCPT and tea polyphenol | Orthotopic liver (H22) carcinoma cell line | [ | ||
| PCL/gelatin | Second carrier ES (core/shell silica nanoparticles) | DOX and Indomethacin | L929 fibroblast cells | [ | ||
| PLGA | Sequential ES | CAR, CPT-11, CIS and CBT | Brain cancer (C6 glioma) | + | [ | |
| Emulsion ES | Paclitaxel and Brefeldin A | Human liver (HepG2) cancer cell line | + | [ | ||
| PLLA | Sequential ES | DCA and oxaliplatin | Cervical cancer (Hela cancer and U14 cancer cell lines) | + | + | [ |
| Second carrier ES (mesoporous silica nanoparticles) | DOX/Ibuprofen | Cervical cancer (Hela cell line) | + | [ | ||
| Blend ES | DOX and HCPT | Human cervical cancer (HeLa cells) | + | [ | ||
| DCA and diisopropylamine dichloroacetate | Colorectal cancer (C26 cells) | + | + | [ | ||
| Oxaliplatin and cyclophosphamide | Human hepatocellular cancer (HCC cells) | + | + | [ | ||
| PCL | Blend ES | (−)-epigallocatechin-3-O-gallate and caffeic acid | Human gastric cancer MKN28 cells | + | [ | |
| Cisplatin and CUR | Human cervical cancer (HeLa cells) | + | + | [ | ||
| CUR and aloe-vera or neem-extract | Lung carcinoma (A549) and breast cancer (MCF-7) | + | [ | |||
| Core-sheath ES | Ibuprofen and DOX | Human hepatocellular carcinoma cell line (HuH-7) | + | [ | ||
| 5-FU and paclitaxel | TNBC cells human triple-negative breast cancer | + | + | [ | ||
| PLLA/PCL | Microfluidic ES | DOX and angiogenesis inhibitor apatinib | Breast cancer (4T1 cells) | + | + | [ |
| PVA | Second carrier ES (mPEG-PCL micelles) | DOX and CUR | Cervical cancer (Hela) cell line | + | [ | |
| Blend ES | Dichloroacetate and Pt(IV) prodrug-backboned micelle | HeLa human cervical cancer cells | + | + | [ | |
| 5-FU: 5-fluorouracil; CAR: Carmustine; CBT: combretastatin; CIS: Cisplatin; CPT-11: irinotecan; CUR: Curcumin; DCA: Sodium dichloroacetate; DOX: Doxorubicin; HCPT: Hydroxycamptothecin; PGC-C18: Poly(glycerol monostearate-co-ε-caprolactone); PLLA: Poly (l-lactic acid); PLGA: (D, L-lactic acid-co-glycolic acid); and SN-38: irinotecan metabolite. | ||||||
Figure 4Development of a barrier membrane using the ES technique for the localized delivery of antibacterial agent in GBR/GTR applications.
Therapeutic agents loaded into electrospun NF implants to promote wound healing.
| Polymeric Fiber | Therapeutic Agent | Purpose | Ref. |
|---|---|---|---|
| PLLA/PVA | Cefazoline | Antibacterial | [ |
| PLGA | [ | ||
| Chitosan/PVA | Lysozyme | Antimicrobial | [ |
| PCL | Chloramphenicol | Antibacterial | [ |
| PLGA | Quercetin | Cell proliferation and adhesion/antibacterial | [ |
| PCL | Rifampicin | Antimicrobial | [ |
| PCL/Gelatin | Metronidazole | Antibacterial | [ |
| PCL | Tauroursodeoxycholic acid | Angiogenesis | [ |
Figure 5Sandwich-type NF skin grafts. Reprinted with permission from ref. [104].
Figure 6Schematic presentation for implementing electrospun NF implants in dental tissue regeneration. Republished under permission from ref. [109].
Electrospun NF coatings for implant-related infections.
| Polymeric Fiber | Antibacterial | Implant | Antibacterial Action against | Ref. |
|---|---|---|---|---|
| PCL/HA | Rifampicin | Titanium | [ | |
| PLGA/PCL | Vancomycin and Rifampicin | Titanium |
| [ |
| PLGA/PCL | Vancomycin/Rifampicin | Titanium |
| [ |
| PLGA | Vancomycin | Titanium |
| [ |
| PLA/PCL/gelatin | Tetracycline | Titanium | [ | |
| Chitosan/polyethylene oxide (PEO) | Vancomycin | Titanium |
| [ |
| Keratin | Silver | Titanium |
| [ |
| PCL/PVA | Doxycycline | Titanium |
| [ |
| Carboxymethylcellulose (CMC)/ PEO | Clindamycin | AISI 316LVM (stainless steel) and Ti90Al6V4 (alloy) | Staphylococci, streptococci, pneumococci, and bacteroides species | [ |
| PLGA/PEO | Gentamycin | Titanium |
| [ |
A literature review of various antibacterial wound dressings prepared using the ES technique.
| Polymeric Chain | Active Agents | Antibacterial Action against | Ref. |
|---|---|---|---|
| PLA/PCL | Tetracycline hydrochloride | [ | |
| PLGA | Cefoxitin sodium |
| [ |
| Amoxicillin |
| [ | |
| PLA | Mupirocin |
| [ |
| coPLA/PEG | Ciprofloxacin hydrochloride, levofloxacin hemihydrate or moxifloxacin hydrochloride |
| [ |
| PLA, PLA/Collagen | Gentamicin | [ | |
| PLLACL | Tetracycline hydrochloride |
| [ |
| PMMA/Nylon 6 | Ampicillin |
| [ |
| PAA | Doxycycline hyclate | [ | |
| Cyclodextrin complex | Triclosan | [ | |
| PCL/PLA | N-halamine | [ | |
| PLA | [ | ||
| PAN | [ | ||
| CAc | Quaternary ammonium salts | [ | |
| Chlorhexidine | [ | ||
| CAc/PEU | Polyhexamethylene biguanide |
| [ |
| PEO/Chitosan | Potassium 5-nitro-8-quinolinolate | [ | |
| PAN | Silver NPs | [ | |
| PLA/Chitosan | [ | ||
| PEO/Chitosan | Antimicrobial peptides (Plantaricin 423 and bacteriocin ST4SA) |
| [ |
| PVA/Chitosan |
| [ | |
| PDLLA/PEO |
| [ |
Abbreviations. CAc: Cellulose acetate; coPLA: poly(l-lactide-co-d,l-lactide); PAA: poly(acrylic acid); PAN: polyacrylonitrile; PEU: polyester urethan; PCL: poly(ϵ-caprolactone); PDLLA: poly(d,l-lactide); PEG: polyethylene glycol; PEO: poly(ethylene oxide); PLA: poly(lactic acid); PLGA: poly(lactide-co-glycolide); PLLACL: poly(l-lactid-co-ε-caprolactone); PMMA: poly(methyl methacrylate); and PVA: polyvinyl alcohol.
Figure 7Wound appearance at 0, 5, 10 and 15 days after grafting with poly(dopamine methacrylamide-co-methyl methacrylate) (MADO)-AgNPs, MADO NF, and control [163].
Figure 8A gelatin (GT)/PCL NF membrane with Ag and Mg ions (GT/PCL-Ag-Mg) was fabricated, and its antibacterial and angiogenesis functions were demonstrated using in vitro and in vivo studies.
Figure 9(a) Schematic diagram of the portable EHD device. (b) A photograph showing the assembly of the mini device held in hand. (c–e) Snapshots of real-time recording of the operation of the mini EHD device generating nanofibers onto a mock wound in situ [188] (Reproduced CC BY license).
Figure 10(a) Fabrication of EPU/FPU/Thymol nanofibrous membranes using the ES portable device. (b) Demonstrative scheme of the breathable, waterproof and antibacterial action of EPU/FPU/Thymol nanofibers. Republished under the permission of Yue et al. [154].
Figure 11Implementing the portable ES device in an intestinal incision. With permission from ref. [192].
Figure 12Schematic diagram of the electric field-modified e-spinning NOCA fibers for liver resection hemostasis.